108 Biocapital Growth Fund, LP
Emerging managerSEC exempt reporting adviser (venture capital exemption).
- Website
- https://108.bio
- HQ
- CT
108 BioCapital is dedicated to advancing medical innovation. Its stated mission is to invest in transformative healthcare solutions that address urgent unmet medical needs, improve patient outcomes, and deliver sustained value to investors. The team includes founder and CEO Dr. Sasha Bakhru, general partners Shahryar Oveissi and Shom Jagtiani, CFO Steve Ward, and associate Connor Smith.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Not stated | Not enough dated deals |
| Sectors | Biotech, Medical devices | Not enough dated deals |
| Regions | US | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| 108 BioCapital Growth Fund, LP 108 BioCapital invests in innovative biotech and medtech companies addressing significant unmet medical needs, seeking transformative healthcare solutions that improve patient outcomes. The firm partners with visionary entrepreneurs and management teams to accelerate growth in diagnostics, therapeutic devices, and personalized medicine. Inferred from the firm's website | 2025 | $10.79M (Form D) | Open, writing first checks |
03 · People across funds
- Sasha Bakhru, Issuer's Co-Founder, Managing Partner & CEO
108 BioCapital Growth Fund, LP (Named on Form D)
- Shom Jagtiani, General Partner
108 BioCapital Growth Fund, LP (Named on Form D)
- Steve Ward, Chief Financial Officer
108 BioCapital Growth Fund, LP (Named on Form D)
- Connor Smith, Associate
- Dr. Sasha Bakhru, Founder & CEO
- Shahryar Oveissi, General Partner
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026